- Creating a Network of Centres of Reference and Fostering Research to Improve
- This study showed a significant improvement in disease control (called "progression-free survival") with trabectedin versus dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) after failure of prior standard therapy with an ...
- Molecular Genetic Testing Should Be Mandatory for Sarcoma Management
- Results showed that the diagnosis was eventually changed by molecular genetics for 16% of the 50 patients with dermatofibrosarcoma, 23% of the 30 patients with dedifferentiated liposarcoma, and 12% of the 112 with Ewing's sarcoma family of tumors.
- Prognostic Nomogram for Retroperitoneal Sarcoma Validated in Large Cohort
- The most common histologic subtype was dedifferentiated liposarcoma (36.6%), followed by well-differentiated liposarcoma (25%), leiomyosarcoma (21.7%), and other subtypes.
- Eribulin Mesylate (Halaven) Succeeds in Late-Stage Liposarcoma Trial
- Based on the significant improvement in OS observed in the preplanned exploratory subgroup analysis of the liposarcoma group, the FDA approved eribulin in January 2016 for the treatment of patients with unresectable or metastatic liposarcoma who have ...
- Rob Ford to be first to participate in cancer research program
- Former Toronto mayor Rob Ford's medical prognosis may lie in the tiny paws of 10 lab mice.
Liposarcoma Prognosis is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Liposarcoma Prognosis books and related discussion.
Suggested News Resources
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.